Table 1.
In vitro susceptibility of all isolates of NME and isolates with β-lactam-resistant phenotypes collected by the SMART global surveillance programme from 2018 to 2020 in Western Europe
| Percentage of isolates susceptible (number of susceptible isolates in TZP- and MEM-resistant isolate subsets) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Phenotype/country/region (n) | IMR | IMP | MEM | FEP | CAZ | TZP | LVX | AMK |
| All isolates | ||||||||
| France (612) | 99.8 | 99.8 | 99.8 | 84.2 | 74.2 | 76.8 | 86.0 | 98.0 |
| Germany (1020) | 99.2 | 98.8 | 99.3 | 89.8 | 82.1 | 83.3 | 90.7 | 99.3 |
| Italy (715) | 98.7 | 87.7 | 87.8 | 70.8 | 65.6 | 71.2 | 69.7 | 90.9 |
| Portugal (482) | 99.4 | 92.5 | 92.1 | 65.4 | 56.2 | 60.0 | 68.3 | 97.5 |
| Spain (1021) | 98.1 | 96.0 | 96.7 | 83.5 | 79.4 | 80.9 | 74.3 | 97.6 |
| UK (564) | 99.8 | 99.1 | 99.3 | 88.1 | 83.3 | 85.1 | 85.6 | 99.7 |
| Western Europe (4414) | 99.1 | 95.9 | 96.1 | 81.6 | 75.0 | 77.6 | 79.8 | 97.2 |
| TZP-resistant isolates | ||||||||
| France (142) | 99.3 (141) | 99.3 (141) | 99.3 (141) | 57.0 (81) | 31.0 (44) | 0 (0) | 67.6 (96) | 94.4 (134) |
| Germany (170) | 95.9 (163) | 94.1 (160) | 95.9 (163) | 72.4 (123) | 38.2 (65) | 0 (0) | 78.8 (134) | 96.5 (164) |
| Italy (206) | 95.6 (197) | 57.8 (119) | 57.8 (119) | 27.2 (56) | 17.0 (35) | 0 (0) | 30.1 (62) | 72.3 (149) |
| Portugal (193) | 98.5 (190) | 81.4 (157) | 80.3 (155) | 32.1 (62) | 13.5 (26) | 0 (0) | 39.4 (76) | 94.8 (183) |
| Spain (195) | 90.3 (176) | 79.0 (154) | 82.6 (161) | 46.2 (90) | 28.2 (55) | 0 (0) | 39.0 (76) | 90.8 (177) |
| UK (84) | 98.8 (83) | 94.1 (79) | 95.2 (80) | 63.1 (53) | 39.3 (33) | 0 (0) | 71.4 (60) | 98.8 (83) |
| Western Europe (990) | 96.0 (950) | 81.8 (810) | 82.7 (819) | 47.0 (465) | 26.1 (258) | 0 (0) | 50.9 (504) | 89.9 (890) |
| MEM-resistant isolatesa | ||||||||
| Italy (64) | 92.2 (59) | 0 (0) | 0 (0) | 1.6 (1) | 0 (0) | 0 (0) | 0 (0) | 34.4 (22) |
| Portugal (21) | 95.2 (20) | 0 (0) | 0 (0) | 0.0 (0) | 0 (0) | 0 (0) | 9.5 (2) | 85.7 (18) |
| Western Europe (106) | 81.1 (86) | 0 (0) | 0 (0) | 0.9 (1) | 0 (0) | 0 (0) | 1.9 (2) | 49.1 (52) |
IMR, imipenem/relebactam; IMP, imipenem; MEM, meropenem; FEP, cefepime; CAZ, ceftazidime; TZP, piperacillin/tazobactam; LVX, levofloxacin; AMK, amikacin.
a
Only countries with at least 20 meropenem-resistant isolates are shown (not shown: France, n = 0; Germany, n = 5; Spain, n = 15; UK, n = 1).